兽用疫苗全球市场规模、份额、趋势和成长分析报告（2026-2034）

预计兽用疫苗市场将从 2025 年的 93.4 亿美元成长到 2034 年的 152.4 亿美元，2026 年至 2034 年的复合年增长率为 5.59%。

由于人们对动物健康的日益关注以及通用感染疾病率的上升，全球兽用疫苗市场正在显着扩张。畜牧业生产的成长以及家禽、牛和猪的感染疾病预防需求正在推动疫苗需求。此外，全球宠物饲养量的激增也加速了医疗保健措施的实施。各国政府和国际组织正在积极推广疫苗接种计划，以确保食品安全和公共卫生。

疫苗研发技术的进步，包括重组疫苗和DNA疫苗，是推动市场成长的主要动力。兽医研发投入的增加以及畜牧业的扩张进一步刺激了市场需求。动物性产品出口活动的扩大要求严格遵守卫生标准，这也提高了疫苗接种率。此外，可支配收入的增加以及人们在宠物医疗保健方面支出意愿的提高，也促进了伴侣动物疫苗市场的稳定成长。

多价疫苗的创新和低温运输物流的改进预计将推动市场前景强劲。新兴经济体畜牧业的扩张将带来巨大的机会。公私合营和政府主导的疫苗宣传活动可望增强市场渗透率。在全球日益关注粮食安全和通用感染疾病预防的背景下，兽用疫苗将继续在永续动物健康管理中发挥至关重要的作用。

目录

第一章：引言

第二章执行摘要

第三章 市场变数、趋势与框架

• 市场谱系展望
• 渗透率和成长前景分析
• 价值链分析
• 法律规范
  • 标准与合规性
  • 监管影响分析
• 市场动态
  • 市场驱动因素
  • 市场限制因素
  • 市场机会
  • 市场挑战
• 波特五力分析
• PESTLE分析

第四章：全球兽用疫苗市场：依技术划分

• 市场分析、洞察与预测
• 减毒活病毒疫苗技术
• 灭活疫苗技术
• 次单位疫苗技术
• 类毒素疫苗技术
• DNA疫苗技术

第五章：全球兽用疫苗市场：依动物种类划分

• 市场分析、洞察与预测
• 伴侣动物
• 家畜
• 水产养殖

第六章：全球兽用疫苗市场：依适应症划分

• 市场分析、洞察与预测
• 口蹄疫
• 新城疫
• 猪繁殖与呼吸综合症（PRRS）
• 犬小病毒
• 布氏桿菌症
• 禽流感
• 其他的

第七章 全球兽用疫苗市场：依通路划分

• 市场分析、洞察与预测
• 兽药
• 动物诊所
• 零售药房
• 网路药房

第八章：全球兽用疫苗市场：依地区划分

• 区域分析
• 北美市场分析、洞察与预测
  • 我们
  • 加拿大
  • 墨西哥
• 欧洲市场分析、洞察与预测
  • 英国
  • 法国
  • 德国
  • 义大利
  • 俄罗斯
  • 其他欧洲国家
• 亚太市场分析、洞察与预测
  • 印度
  • 日本
  • 韩国
  • 澳洲
  • 东南亚
  • 其他亚太国家
• 拉丁美洲市场分析、洞察与预测
  • 巴西
  • 阿根廷
  • 秘鲁
  • 智利
  • 其他拉丁美洲国家
• 中东和非洲市场分析、洞察与预测
  • 沙乌地阿拉伯
  • UAE
  • 以色列
  • 南非
  • 其他中东和非洲国家

第九章 竞争情势

• 最新趋势
• 公司分类
• 供应链和销售管道合作伙伴（根据现有资讯）
• 市场占有率和市场定位分析（基于现有资讯）
• 供应商情况（基于现有资讯）
• 策略规划

第十章：公司简介

• 主要公司的市占率分析
• 公司简介
  • Merck & Co. Inc.（MSD Animal Health）
  • Zoetis Services LLC
  • Boehringer Ingelheim International GmbH And Elanco（Eli Lilly）
  • Ceva
  • Kemin Industries Inc
  • Virbac
  • Jinyu Biotechnology Co. Ltd
  • Vaxxinova
  • Indian Immunologicals Ltd
  • Phibro Animal Health Corporation And Others

The Veterinary Vaccine Market size is expected to reach USD 15.24 Billion in 2034 from USD 9.34 Billion (2025) growing at a CAGR of 5.59% during 2026-2034.

The Global Veterinary Vaccine Market has expanded significantly due to increasing awareness of animal health and the rising incidence of zoonotic diseases. Livestock production growth and the need to prevent infectious diseases in poultry, cattle, and swine have fueled vaccine demand. Companion animal ownership has also surged globally, encouraging preventive healthcare measures. Governments and international organizations actively promote vaccination programs to ensure food safety and public health protection.

Market growth is driven by technological advancements in vaccine development, including recombinant and DNA-based vaccines. Increased investment in veterinary research and the expansion of animal husbandry industries further stimulate demand. Growing export activities of animal-derived products require strict health compliance, reinforcing vaccination adoption. Additionally, rising disposable incomes and willingness to spend on pet healthcare contribute to the steady expansion of the companion animal vaccine segment.

The market's future outlook remains robust, supported by innovations in multivalent vaccines and improved cold chain logistics. Expanding livestock industries in emerging economies will offer substantial opportunities. Public-private partnerships and government-led immunization campaigns are expected to strengthen market penetration. As global focus on food security and zoonotic disease prevention intensifies, veterinary vaccines will continue to play a vital role in sustainable animal health management.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Technology

• Attenuated Live Vaccines Technology
• Inactivated Vaccines Technology
• Subunit Vaccines Technology
• Toxoid Vaccines Technology
• Dna Vaccines Technology

By Animal

• Companion Animals
• Livestock Animals
• Aquaculture

By Disease Indication

• Foot And Mouth Disease (FMD)
• Newcastle Disease
• Porcine Reproductive and Respiratory Syndrome (PRRS)
• Canine Parvovirus
• Brucellosis
• Avian Influenza
• Others

By Distribution Channel

• Veterinary Hospital Pharmacies
• Veterinary Clinics
• Retail Pharmacies
• Online Pharmacies

COMPANIES PROFILED

• Merck Co Inc MSD Animal Health, Zoetis Services LLC, Boehringer Ingelheim International GmbH and Elanco Eli Lilly, Ceva, Kemin Industries Inc, Virbac, Jinyu Biotechnology Co Ltd, Vaxxinova, Indian Immunologicals Ltd, Phibro Animal Health Corporation and Others

We can customise the report as per your requriements

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL VETERINARY VACCINE MARKET: BY TECHNOLOGY 2022-2034 (USD MN and Million Doses)

• 4.1. Market Analysis, Insights and Forecast Technology
• 4.2. Attenuated Live Vaccines Technology Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
• 4.3. Inactivated Vaccines Technology Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
• 4.4. Subunit Vaccines Technology Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
• 4.5. Toxoid Vaccines Technology Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
• 4.6. Dna Vaccines Technology Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)

Chapter 5. GLOBAL VETERINARY VACCINE MARKET: BY ANIMAL 2022-2034 (USD MN and Million Doses)

• 5.1. Market Analysis, Insights and Forecast Animal
• 5.2. Companion Animals Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
• 5.3. Livestock Animals Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
• 5.4. Aquaculture Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)

Chapter 6. GLOBAL VETERINARY VACCINE MARKET: BY DISEASE INDICATION 2022-2034 (USD MN and Million Doses)

• 6.1. Market Analysis, Insights and Forecast Disease Indication
• 6.2. Foot And Mouth Disease (FMD) Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
• 6.3. Newcastle Disease Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
• 6.4. Porcine Reproductive and Respiratory Syndrome (PRRS) Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
• 6.5. Canine Parvovirus Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
• 6.6. Brucellosis Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
• 6.7. Avian Influenza Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
• 6.8. Others Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)

Chapter 7. GLOBAL VETERINARY VACCINE MARKET: BY DISTRIBUTION CHANNEL 2022-2034 (USD MN and Million Doses)

• 7.1. Market Analysis, Insights and Forecast Distribution Channel
• 7.2. Veterinary Hospital Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
• 7.3. Veterinary Clinics Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
• 7.4. Retail Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
• 7.5. Online Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)

Chapter 8. GLOBAL VETERINARY VACCINE MARKET: BY REGION 2022-2034(USD MN and Million Doses)

• 8.1. Regional Outlook
• 8.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN and Million Doses)
  • 8.2.1 By Technology
  • 8.2.2 By Animal
  • 8.2.3 By Disease Indication
  • 8.2.4 By Distribution Channel
  • 8.2.5 United States
  • 8.2.6 Canada
  • 8.2.7 Mexico
• 8.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN and Million Doses)
  • 8.3.1 By Technology
  • 8.3.2 By Animal
  • 8.3.3 By Disease Indication
  • 8.3.4 By Distribution Channel
  • 8.3.5 United Kingdom
  • 8.3.6 France
  • 8.3.7 Germany
  • 8.3.8 Italy
  • 8.3.9 Russia
  • 8.3.10 Rest Of Europe
• 8.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN and Million Doses)
  • 8.4.1 By Technology
  • 8.4.2 By Animal
  • 8.4.3 By Disease Indication
  • 8.4.4 By Distribution Channel
  • 8.4.5 India
  • 8.4.6 Japan
  • 8.4.7 South Korea
  • 8.4.8 Australia
  • 8.4.9 South East Asia
  • 8.4.10 Rest Of Asia Pacific
• 8.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN and Million Doses)
  • 8.5.1 By Technology
  • 8.5.2 By Animal
  • 8.5.3 By Disease Indication
  • 8.5.4 By Distribution Channel
  • 8.5.5 Brazil
  • 8.5.6 Argentina
  • 8.5.7 Peru
  • 8.5.8 Chile
  • 8.5.9 South East Asia
  • 8.5.10 Rest of Latin America
• 8.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN and Million Doses)
  • 8.6.1 By Technology
  • 8.6.2 By Animal
  • 8.6.3 By Disease Indication
  • 8.6.4 By Distribution Channel
  • 8.6.5 Saudi Arabia
  • 8.6.6 UAE
  • 8.6.7 Israel
  • 8.6.8 South Africa
  • 8.6.9 Rest of the Middle East And Africa

Chapter 9. COMPETITIVE LANDSCAPE

• 9.1. Recent Developments
• 9.2. Company Categorization
• 9.3. Supply Chain & Channel Partners (based on availability)
• 9.4. Market Share & Positioning Analysis (based on availability)
• 9.5. Vendor Landscape (based on availability)
• 9.6. Strategy Mapping

Chapter 10. COMPANY PROFILES OF GLOBAL VETERINARY VACCINE INDUSTRY

• 10.1. Top Companies Market Share Analysis
• 10.2. Company Profiles
  • 10.2.1 Merck & Co. Inc. (MSD Animal Health)
  • 10.2.2 Zoetis Services LLC
  • 10.2.3 Boehringer Ingelheim International GmbH And Elanco (Eli Lilly)
  • 10.2.4 Ceva
  • 10.2.5 Kemin Industries Inc
  • 10.2.6 Virbac
  • 10.2.7 Jinyu Biotechnology Co. Ltd
  • 10.2.8 Vaxxinova
  • 10.2.9 Indian Immunologicals Ltd
  • 10.2.10 Phibro Animal Health Corporation And Others